Actively Recruiting

Phase 1
Age: 18Years - 60Years
All Genders
NCT06809712

Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Led by He Huang · Updated on 2025-02-05

29

Participants Needed

1

Research Sites

273 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo HSCT) but lack suitable donors. This project plans to use highly mismatched unrelated HLA mismatched donors. Ultimately, an unrelated human leukocyte antigen (HLA) mismatched allo HSCT transplantation plan will be established to improve the disease prognosis of this group of patients and truly enter the era of "everyone has a donor" for allo HSCT.

CONDITIONS

Official Title

Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Who Can Participate

Age: 18Years - 60Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 60 years with blood cancers needing hematopoietic stem cell transplantation
  • No matched blood donors with HLA high-resolution typing ≥ 9/10
  • Difficulty finding matched donors due to urgent medical condition
  • No suitable haploidentical HLA matched donor available
  • Suitable unrelated HLA mismatched donors available (HLA typing < 9/10)
  • Participant or legal representative has signed informed consent before study start
Not Eligible

You will not qualify if you...

  • Severe liver dysfunction (alanine aminotransferase > 2.5 times upper limit of normal)
  • Severe kidney dysfunction (blood creatinine > 1.5 times upper limit of normal)
  • Cardiopulmonary dysfunction (NYHA III/IV heart function, ejection fraction < 50%, severe lung dysfunction)
  • Active infections
  • ECOG performance status ≥ 2 points
  • Active secondary tumors
  • Severe central nervous system or mental illness preventing informed consent
  • Other contraindications to allogeneic hematopoietic stem cell transplantation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, China, 310003

Actively Recruiting

Loading map...

Research Team

Y

Yishan Ye, MD., PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation | DecenTrialz